Injective CEO Eric Chen Expects US INJ-Linked ETF by 2027

A CEO's expectation is not a regulatory signal, and Chen's own refusal to give a timeline is the more telling detail. What matters is that two issuers have already filed, so the INJ ETF question now sits with the SEC rather than with Injective's leadership. For token holders, the filing pipeline is the substantive development; the executive forecast is commentary on top of it. Whether those applications advance, stall, or join the broader queue of altcoin ETF requests is the open question worth tracking.